Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of imlifidase plus standard of care versus standard of care alone in severe anti-GBM antibody disease
2022-500121-33-01Phase 3Completed
- Sponsor
- Hansa Biopharma
- Start
- Mar 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 14
01
Overview
Phase 3, randomised, open-label trial of efgartigimod alfa, cyclophosphamide, methylprednisolone, prednisolone, trimethoprim and 2 more in anti-glomerular basement membrane disease (2 arms), sponsored by Hansa Biopharma. Primary endpoint: Renal function at 6 months. Started Mar 2023; status: completed.
02
Drugs
efgartigimod alfacyclophosphamidemethylprednisoloneprednisolonetrimethoprim
03
Conditions
anti-glomerular basement membrane disease
Beyond the preview
Go deeper on 2022-500121-33-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500121-33-01.